Wierda WG, Allan JN, Siddiqi T, Kipps TJ, et al. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol 2021 Oct 7:JCO2100807. doi: 10.1200/JCO.21.00807.
PMID: 34618601